Table 4. Univariate analysis of prognostic factors.
| Variable | n | Median survival (months) | HR | 95%CI | P | ||
|---|---|---|---|---|---|---|---|
| Age, years, < 60: ≥ 60 | 47/30 | 10.2/8.9 | 0.996 | 0.969–1.024 | 0.119 | ||
| Gender,Male:Female | 69/8 | 6.0/5.1 | 0.952 | 0.442–2.383 | 0.706 | ||
| AFP, μg/L, < 20: ≥ 20 | 12/65 | 6.2/5.9 | 1.000 | 1.000–1.001 | 0.885 | ||
| ALT, IU/L, < 44: ≥ 44 | 26/51 | 5.3/6.0 | 0.998 | 0.989–1.006 | 0.368 | ||
| AST, IU/L, < 44: ≥ 44 | 16/61 | 4.18/6.4 | 1.008 | 1.000–1.016 | 0.063 | ||
| Albumin,g/l, < 35: ≥ 35 | 14/63 | 4.26/6.31 | 0.902 | 0.761–1.069 | 0.236 | ||
| Total bilirubin,μmol/L, < 17.1: ≥ 17.1 | 38/39 | 5.6/6.3 | 1.009 | 0.983–1.037 | 0.615 | ||
| HBsAg,Positive : Negative | 67/10 | 5.9/4.3 | 0.829 | 0.376–1.827 | 0.423 | ||
| Tumor number, Single:Multiple | 43/34 | 5.7/6.1 | 0.817 | 0.491–1.359 | 0.804 | ||
| Diameter(cm), ≤ 5: > 5 | 11/66 | 10.2/5.4 | 1.096 | 1.022–1.175 | 0.031 | ||
| TACE sessions (n), 1 : > 1 | 47/30 | 6.6/4.8 | 0.863 | 0.610–1.222 | 0.226 | ||
| Classification of PVTT (n) | 1.241 | 0.927–1.661 | 0.111 | ||||
| Type I | 20 | 8.5 | |||||
| Type II | 31 | 5.1 | |||||
| Type III | 20 | 5.6 | |||||
| Type IV | 6 | 2.5 | |||||
| Accumulation of Lipiodol (n) | 1.733 | 1.347–2.231 | 0.000 | ||||
| I | 9 | 12.5 | |||||
| II | 18 | 8.7 | |||||
| III | 22 | 4.0 | |||||
| IV | 28 | 3.5 | |||||